Gilder Gagnon Howe & Co’s Burning Rock Biotech BNR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,516	Closed	-$271K	–	395
2021 Q3	$271K	Sell	1,516 -67,148	-98%	-$14.9M	﹤0.01%	362
2021 Q2	$20.2M	Sell	68,664 -149	-0.2%	-$44.1K	0.1%	159
2021 Q1	$18.5M	Buy	68,813 +67,940	+7,782%	+$20.7M	0.1%	162
2020 Q4	$202K	Buy	873 +743	+572%	+$199K	﹤0.01%	298
2020 Q3	$33K	Sell	130 -83	-39%	-$19.7K	﹤0.01%	324
2020 Q2	$58K	Buy	+213	New	+$58.4K	﹤0.01%	289

Other funds holding BNR

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gilder Gagnon Howe & Co's BNR Position: Q4 2021 in Review

Gilder Gagnon Howe & Co sold out of Burning Rock Biotech (BNR) in Q4 2021, closing a stake of 1,516 shares — an estimated $271K sold.

Gilder Gagnon Howe & Co first reported a position in BNR in Q2 2020 and held it in 6 quarters. The position peaked at $20.2M in Q2 2021. 62 funds tracked by Wall St. Rank hold BNR as of Q4 2021.

Gilder Gagnon Howe & Co reported no remaining Burning Rock Biotech position as of Q4 2021 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 1,516 Burning Rock Biotech shares in Q4 2021, an estimated $271K.
Gilder Gagnon Howe & Co first reported a position in Burning Rock Biotech in Q2 2020 and held it in 6 quarters.
Gilder Gagnon Howe & Co's Burning Rock Biotech position peaked at $20.2M in Q2 2021.
62 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2021, filed 14 Feb 2022.